Chemotherapy plus bevacizumab in the first-line treatment of non-small cell lung cancer: benefits, risks and limitations

Author: Grossi F.  

Publisher: Springer Publishing Company

ISSN: 1865-5041

Source: memo - Magazine of European Medical Oncology, Vol.1, Iss.1, 2008-03, pp. : 13-16

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content